Wall Street Thinks SpaceX Is a Buy. Here's Why I'm Not So Sure

SpaceX’s Q2 revenue jumped 92% YoY to $7.8B and its net loss narrowed to $541M (from $1B), but the stock is still down from its $150 IPO price. The article attributes weakness to potential near-term selling after lockup expiries and a very rich valuation (P/S of 65.7) that leaves little margin of error. Upside of ~50%+ is argued to be possible only if catalysts (e.g., more Starship test successes, large AI deals, limited insider selling) play out without setbacks.

Analysis

SPCX is behaving less like a compounder and more like a long-duration option on execution, which is a dangerous setup when the valuation already discounts a clean path through multiple binary milestones. In that regime, the stock can disappoint even if the operating business keeps improving, because the market is paying for acceleration in launch cadence, monetization, and broader platform expansion—not just steady progress. The key second-order effect is multiple compression: any sign that those catalysts slip by even one quarter can trigger a much larger de-rating than the fundamental miss would imply.

The near-term technical risk is supply, not demand. As more shares become eligible for sale into mid-next year, the marginal buyer has to absorb insider distribution while also underwriting a premium that leaves little room for error. That overhang matters most in the 1-3 month window around lockup dates and earnings, where even neutral results can fail to support the stock.

Contrarian view: the consensus is probably underestimating how hard it is to convert engineering progress into durable equity returns at this valuation. The market is implicitly assuming multiple future winners at once; if only one of the AI, satellite broadband, or launch monetization arcs lags, the stock can underperform for 6-18 months. The thesis is only falsified if the company demonstrates repeated execution plus clear evidence that insider supply is absorbed without price damage; absent that, the risk/reward remains skewed to the downside.

Key Decisions for Investors

• Avoid initiating fresh long exposure in SPCX at current levels; if already long, trim on strength and treat it as a catalyst-trading position rather than a core holding.
• Enter a 3-6 month put spread on SPCX into post-lockup strength to express the view that supply overhang plus valuation can compress the multiple even without an operational miss; risk/reward is attractive if the stock reprices 15-25% lower.
• Set a watch item for insider selling and secondary supply through mid-next year; if free float expands faster than demand, use that as the trigger to add to a short or hedge existing exposure.
• If SPCX breaks lower on an earnings/guidance event while launch cadence or monetization metrics fail to inflect, add to the short on a 1-3 month horizon; cover if the company shows two consecutive quarters of accelerating growth plus no meaningful lockup-driven selling.
• Do not pair this against GOOG/GOOGL absent clearer disclosure on customer concentration; the cleaner trade is SPCX short versus cash, not a complex cross-asset hedge.